Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Zymeworks

NYSE ZYME
$8.81 0.0000 0.0000%
Today share price
Canada
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 18 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

671.75M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
518.45M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.02
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
76.25M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-15.21 %

Upcoming events Zymeworks

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Zymeworks

Stock analysis Zymeworks

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-5.33 47.56
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
1.45 27.51
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-3.92 14.48
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
1.16 2.03
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-28.76 74.85

Price change Zymeworks per year

24.82$ 59.03$
Min Max

Summary analysis Zymeworks

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Zymeworks

Revenue and net income Zymeworks

All parameters

Stock news Zymeworks

All news
4 January в 14:40

Zymeworks Says It Has Resources to Make Progress in 2024, 2025

4 January в 14:40

Zymeworks Says It Has Resources to Make Progress in 2024, 2025

18 May 2023 в 15:50

Zymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYME

18 May 2023 в 15:50

Zymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYME

8 March 2023 в 19:15

Zymeworks Shares Rise 8% After 4Q Earnings, Revenue Beat

8 March 2023 в 19:11

Zymeworks Shares Rise 8% After 4Q Earnings, Revenue Beat

19 January 2023 в 16:11

Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals

21 December 2022 в 21:45

Zymeworks Shares Rise 20% After Jazz Pharma Exercises Zanidatamab Option

21 December 2022 в 21:45

Zymeworks Shares Rise 20% After Jazz Pharma Exercises Zanidatamab Option

19 October 2022 в 17:40

Zymeworks Shares Rally After Zanidatamab Pact With Jazz >ZYME

19 October 2022 в 17:35

Zymeworks Shares Rally After Zanidatamab Pact With Jazz >ZYME

19 October 2022 в 15:40

Zymeworks, Jazz agree to licensing deal for cancer drug

19 October 2022 в 13:45

Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact

19 October 2022 в 13:40

Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact

6 September 2022 в 21:25

Zymeworks Down After Reporting Preliminary Cancer-Drug Results

6 September 2022 в 21:20

Zymeworks Down After Reporting Preliminary Cancer-Drug Results

20 May 2022 в 19:05

Toronto Stocks Fall; Zymeworks Rises After Rejecting Buyout

20 May 2022 в 19:05

Toronto Stocks Fall; Zymeworks Rises After Rejecting Buyout

20 May 2022 в 16:55

Zymeworks rejects 'unsolicited, opportunistic' buyout bid by UAE-based All Blue Falcons

20 May 2022 в 16:46

Zymeworks Rejects Bid From All Blue as 'Opportunistic' >ZYME

About company Zymeworks

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Address:
1385 West 8th Avenue, Vancouver, BC, Canada, V6H 3V9
Company name: Zymeworks
Issuer ticker: ZYME
ISIN: CA98985W1023
Country: Canada
Exchange: NYSE
Currency: $
IPO date: 2017-04-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.zymeworks.com

On which stock exchange are Zymeworks (ZYME) stocks traded?

Zymeworks (ZYME) stocks are traded on NYSE.

What is the ticker of Zymeworks stocks (ZYME)?

The stock ticker of Zymeworks’s stocks or in other words, the code is ZYME. The stocks are currently listed on the NYSE exchange.

In which sector and industry does Zymeworks (ZYME) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Zymeworks (ZYME) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Zymeworks (ZYME) stocks traded?

Zymeworks (ZYME) stocks are traded on the NYSE exchange in dollars.

What is the price of Zymeworks (ZYME) stocks today?

The current price of Zymeworks stocks on 13.05.2024 is 8.81 dollars. per share.

What is the dynamics of Zymeworks (ZYME) stocks from the beginning of the year?

Zymeworks (ZYME) quotes have increased by -15.13% from the beginning of the year up to 8.81 dollars. per 1 stocks.

How much did Zymeworks (ZYME) stocks increase in мае 2024?

This month Zymeworks (ZYME) quotes have increased by 0.57% to 8.81 dollars. per share.

How much are Zymeworks (ZYME) stocks worth?

Today, on October, 13.05.2024 Zymeworks’s (ZYME) stocks cost 8.81 dollars..

What is the market capitalization of Zymeworks (ZYME)?

Capitalization is the market value of Zymeworks (ZYME) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 13.05.2024, the market capitalization of Zymeworks (ZYME) is estimated at about 671746272 dollars.